Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of famotidine on levodopa-induced dyskinesia in Parkinson's disease
IRCT20231016059737N2Phase 3Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of famotidine in Parkinson's disease (PD) and drug-induced dyskinesia, sponsored by Shiraz University of Medical Sciences. Started Oct 2025; status: completed.
02
Drugs
famotidine
03
Conditions
Parkinson's disease (PD)drug-induced dyskinesia
Beyond the preview
Go deeper on IRCT20231016059737N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20231016059737N2.